Background Liquid biopsy has been widely researched for early diagnosis, prognostication
and disease monitoring in lung cancer, but there is a need to investigate its clinical utility for …

Simple Summary Early-stage disease non-small cell lung cancer has better outcomes than
advanced disease, but 5-year survival rates can drop to approximately 50% in cases of …

Liquid biopsy in lung cancer is evolving as an important added tool for screening, early
detection, monitoring, and even prognostication of lung cancer. Guidelines and expert …

Introduction In the current era of personalized medicine, liquid biopsy has acquired a
relevant importance in patient management of advanced stage non-small cell lung cancer …

Molecularly targeted therapies and immune checkpoint inhibitors have markedly improved
the therapeutic management of advanced lung cancer. However, it still remains the leading …

Lung cancer, a leading cause of cancer-related mortality, has a low rate of early diagnosis
and a poor prognosis for advanced stages. Recent advances in further mastery of the …

The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …

Simple Summary Lung cancer is the leading cause of cancer death worldwide. Detecting
lung malignancies promptly is essential for any anticancer treatment to reduce mortality and …

Liquid biopsy is now considered a valuable diagnostic tool for advanced metastatic non-
small cell lung cancer (NSCLC). In NSCLC, circulating tumor DNA (ctDNA) analysis has …

Lung cancer is the leading cause of cancer-associated deaths worldwide. Surgery is the
standard treatment for early-stage non-small cell lung cancer (NSCLC). However, 30% to …